Pharmides
ActiveSummary
Pharmides has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €115,992 and a net result of €30,503. Equity is growing by about 40% per year across the filed financial years. Its solvency ranks better than 93% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Highest result from 2022 to 2025net €30,503 ▲7.2%
Operating result €39,167, net result €30,503, both a record.
31-12
Financial
Equity above €100,000equity €115,992 ▲35.7%
A profit in every financial year since 2022 builds equity to €115,992.
25-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
25-06
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
27-06
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.